Status:
COMPLETED
Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
Lead Sponsor:
St. Luke's-Roosevelt Hospital Center
Collaborating Sponsors:
Gilead Sciences
Conditions:
HIV
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Study subjects receiving the antiretroviral drugs Combivir or trizivir, will be randomized to switch to Truvada-containing highly active antiretroviral therapy (HAART) or to continue on Combivir or on...
Detailed Description
None different from the summary description above.
Eligibility Criteria
Inclusion
- infection with human immunodeficiency virus (HIV) with undetectable viral load
- on Combivir or trizivir
- able to exercise and sign consent
Exclusion
- other active illness
- contraindication to magnetic resonance imaging (MRI) scanning or maximal exercise.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00960622
Start Date
August 1 2006
End Date
July 1 2009
Last Update
March 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Luke's-Roosevelt Hospital Center
New York, New York, United States, 10025